Clinical Trials Logo

Barrett Esophagus clinical trials

View clinical trials related to Barrett Esophagus.

Filter by:

NCT ID: NCT00885469 Completed - Clinical trials for Gastroesophageal Reflux Disease

PillCam® ESO 2 in Esophageal Pathologies

MA-76
Start date: December 2007
Phase:
Study type: Observational

Study Hypothesis: - PillCam™ ESO-2 will demonstrate equivalent accuracy parameters as compared to blinded esophagogastroduodenoscopy (EGD) in detecting suspected Barrett's esophagus, detecting and grading esophagitis. - PillCam™ ESO will demonstrate all safety parameters as compared to EGD - PillCam™ ESO-2 will demonstrate better patient's satisfaction as compared to EGD

NCT ID: NCT00872755 Completed - Dysphagia Clinical Trials

Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD)

Start date: January 2002
Phase: Phase 4
Study type: Interventional

Laparoscopic Nissen Fundoplication has established itself as the procedure of choice in the surgical management of the majority of patients suffering from gastroesophageal reflux disease (GERD). Postoperative paraesophageal herniation has incidence ranges up to 7% in the immediate postoperative period. This randomized controlled study was scheduled to investigate the role of the posterior gastropexy, in combination with laparoscopic Nissen fundoplication, in prevention of paraesophageal herniation and improvement of postoperative results, in surgical treatment of GERD.

NCT ID: NCT00858858 Completed - Clinical trials for Gastroesophageal Reflux Disease

Clinical Studies on Bile Acids in Barrett's Esophagus

Start date: March 2009
Phase: N/A
Study type: Interventional

This study has two major goals: 1. To determine the effects of bile salts on causing DNA injury and activating signaling pathways that promote growth in cells from the esophagus of patients who have gastroesophageal reflux disease (GERD) 2. To determine whether changes in bile composition induced by treating patients with a bile salt called ursodeoxycholic acid (UDCA) can alter DNA injury, signaling pathway activation and other types of damage in cells from the esophagus of patients who have GERD.

NCT ID: NCT00848237 Completed - Barrett Esophagus Clinical Trials

HALO Patient Registry: Ablation of Barrett's Esophagus

Start date: July 2007
Phase: N/A
Study type: Interventional

The HALO Patient Registry is a prospective/retrospective, multi-center patient registry. It provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD). The primary objective is to provide a tool for participating physician investigators to collect outcomes data related to the use of the HALO Ablation Systems.

NCT ID: NCT00844077 Completed - Barrett's Esophagus Clinical Trials

Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus

Start date: October 2007
Phase: N/A
Study type: Observational

Barrett's esophagus can progress to esophageal cancer, but it doesn't always. Current treatment is frequent surveillance via upper endoscopy with multiple biopsies to look for changes (dysplasia). Pathologists vary dramatically in their interpretation of Barrett's Metaplasia versus dysplasia and consensus is very difficult to achieve. The investigators propose a longitudinal study of subjects with confirmed Barrett's intestinal metaplasia without dysplasia to look for predictive factors for transformation to dysplasia or cancer. Potential biomarkers can be found in serum, plasma, urine, frozen or fixed Barrett's and Normal esophageal mucosa. In addition, the investigators are testing a brushing technique from CDx, Inc. for predictive factors. Subjects must have pathologically confirmed Barrett's intestinal metaplasia without history of dysplasia to be on this longitudinal study.

NCT ID: NCT00795184 Completed - Adenocarcinoma Clinical Trials

Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy

DONTBIOPCE
Start date: November 2008
Phase: N/A
Study type: Interventional

This study will collect data from patients routinely undergoing a endoscopic surveillance and Cellvizio endomicroscopy procedure due to confirmed Barrett's esophagus. The objective is to determine if endomicroscopy images collected using the marketed Cellvizio device may help endoscopists more accurately diagnose, in conjunction with traditional tissue sampling techniques, whether a suspected lesion is malignant or benign.

NCT ID: NCT00754468 Completed - Esophageal Cancer Clinical Trials

Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.

ESODOI
Start date: February 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the treatment effect, depth of injury, and side effects using technology involving the spray of liquid nitrogen through a catheter (CryoSpray AblationTM, "CSA" or "cryospray therapy") onto healthy tissue via esophagogastroduodenoscopy (EGD) using surgical resection specimens from subjects undergoing esophagectomy.

NCT ID: NCT00747448 Completed - Esophageal Cancer Clinical Trials

CryoSpray Ablation (TM) GI Patient Registry

Start date: May 2009
Phase: N/A
Study type: Observational

The purpose of this study is to create a patient registry to collect and analyze post-510K approval information on subjects treated endoscopically with the CryoSpray Ablation™ System.

NCT ID: NCT00747136 Terminated - Barrett's Esophagus Clinical Trials

WavSTAT® Optical Biopsy System to Target Esophageal Biopsies

Start date: August 2008
Phase: N/A
Study type: Observational

The purpose of this study is to demonstrate the clinical utility of the WavSTAT Optical Biopsy System as an adjunctive tool to improve the endoscopist's clinical sensitivity to identify dysplasia or cancer in the esophagus.

NCT ID: NCT00737802 Terminated - GERD Clinical Trials

In Vivo Anatomy, Physiology, Mechanics and Function of the Lower Esophageal Sphincter

Start date: April 12, 2013
Phase:
Study type: Observational

The purpose of this study is: - To study the components of the gastroesophageal junction high-pressure zone individually and as a group, by pharmacologically eliminating or accentuating the pressure profile generated by the smooth muscle components. - To differentiate the gastric sling fibers from the clasp fibers based on the spatial orientation of these muscle groups.